A patient returns after sclerotherapy with a tender lump along a treated vein or skin discoloration over it. The vein may have responded to treatment, but the patient still has a problem that deserves attention. We need to determine whether retained intravascular coagulum is contributing to the finding and whether it can be evacuated.
Painful lumps and staining are the recognized trade-off of foam sclerotherapy. Foam closes the vein where it lies and leaves blood in the treated segment, and that blood can clot.
My indication for microthrombectomy is symptoms or skin discoloration. The finding, its location and the contents of the treated vein guide the decision. A scheduled follow-up is an opportunity to assess the result; it is not by itself an indication to perform another procedure.
What is being removed
Microthrombectomy in this setting means evacuating retained blood and clot from a superficial vein after sclerotherapy. It differs from ambulatory phlebectomy, which removes a vein segment, and from intraprocedural foam expression, which empties foam and blood during the original treatment.
The intended long-term result of sclerotherapy is fibrosis of the treated vein. Thrombus within its lumen is not the final therapeutic objective.1 The German phlebology society’s sclerotherapy guideline gives the reason: a vein that has only thrombosed can recanalize, whereas a vein transformed into a cord of connective tissue cannot.1 The clot is not what makes the treatment durable, so evacuating retained clot does not remove the result the treatment is meant to achieve. A palpable treated segment therefore does not, by itself, establish persistent reflux or treatment failure. There may be a specific local problem that can be addressed without repeating the entire venous treatment.
Symptoms and discoloration need an explanation
The first step is to relate the patient’s concern to the treated area. Was the discomfort present before treatment? Is the discoloration new? Does the tender lump or cord follow an injected vein? Is there a discrete segment containing material that could be evacuated?
Discoloration is not a single diagnosis. Blood visible within a superficial treated vein, pigmentation after treatment, bruising and pre-existing gaiter-area skin changes can look different and have different implications. The German guideline reports transient skin pigmentation in 0.3% to 30% of patients, probably more often after foam than after liquid sclerotherapy.1 In general the pigmentation fades slowly, over weeks or months.1
Why a retained clot can stain the skin is the reasoning behind microthrombectomy. As the clot breaks down, the hemoglobin in its red cells is degraded and the iron is left in the skin as hemosiderin. The authors of the randomized microthrombectomy trial named hemosiderin from the breakdown of the venous thrombus as the possible cause of pigmentation after sclerotherapy.2 The same chain explains why early evacuation is expected to reduce staining, since less clot is left to break down.
Microthrombectomy addresses material in the vein lumen. It does not mechanically remove pigment already deposited in the skin. The presence of discoloration prompts assessment for retained coagulum; it does not guarantee that drainage will erase the color or that there is anything left to drain.
The response also depends on the extent of the symptoms. A localized treated segment needs to be distinguished from spreading inflammation, thrombus extending beyond the injected vein, infection or DVT. The German guideline’s criterion is location and extent. An inflammatory reaction confined to the injected segment of vein, as long as it does not exceed an ordinary size, is usually a reaction to sclerotherapy and should not be interpreted as superficial venous thrombosis. Thrombosis in a vein that was not injected, or clearly extending beyond the injected segment, is superficial venous thrombosis.1 Superficial venous thrombosis is often wrongly perceived as benign.3 When it is suspected, an ultrasound should be obtained.
When ultrasound changes the decision
Ultrasound can clarify the location and contents of a deeper or less easily defined treated segment and can assist a targeted puncture. Where symptoms raise concern for extension or DVT, the study needs to evaluate that concern, rather than simply confirm that the visibly treated vein is closed.
The 2023 venous guideline recommends early duplex ultrasound for symptomatic patients after thermal or nonthermal ablation to assess for ablation-related thrombus extension or DVT.4 A previous negative study is a record of that examination, not a guarantee about a later episode of pain or swelling.
The historical foam phlebectomy series included a DVT with pulmonary embolism several weeks after a negative one-week ultrasound. The lesson is to reassess new symptoms on their merits. Evacuating a superficial lump is not treatment for DVT.
Timing is part of the assessment
The clot needs to be accessible and amenable to evacuation. A firm organized segment may not behave like a collection of retained liquid blood or soft coagulum. The calendar alone cannot establish what is present.
The principal randomized microthrombectomy study performed the procedure one to three weeks after sclerotherapy. It included 101 patients and compared treated and untreated halves of a selected area within each patient. The trial treated small veins with sodium tetradecyl sulfate (Sotradecol): 0.25% for veins 1 mm or less in diameter (50 patients) and 0.50% for veins 3 mm or less (51 patients). Assessment at 16 weeks found less pigmentation in the group with veins no larger than 1 mm; the group with veins up to 3 mm did not show a significant pigmentation benefit, although patients reported faster relief of pain and inflammation.2
That trial supports a role for microthrombectomy, but it does not establish a universal timing rule or the same cosmetic benefit after foam treatment of larger varicosities. The one-to-three-week interval is the study protocol. My clinical indication remains symptoms or skin discoloration.
In the foam phlebectomy series, microthrombectomy was performed at the three-to-five-week assessment for discomfort or discoloration. That is the follow-up interval reported in that series, rather than a requirement to wait until then when a patient needs assessment earlier.
The procedure and its limits
The published approaches are needle aspiration or a small opening through which superficial coagulum can be expressed.1 The German guideline’s Recommendation 10 states that superficial clots can be removed to reduce the risk of hyperpigmentation.1
A useful clinical endpoint is decompression of the selected segment and improvement in the local finding. Forceful manipulation of a firm segment that will not empty is not evidence of a successful evacuation. If the examination does not identify accessible retained material, the diagnosis and next step should be reconsidered. Persistent discoloration does not by itself mean that more clot should be expressed.
Relationship to foam phlebectomy
During foam phlebectomy, foam and blood are expressed through selected openings at the original procedure. One of my reasons for combining the techniques was to reduce the burden of retained coagulum and the need for later microthrombectomy.
My historical experience still included microthrombectomy for discomfort or discoloration after combined treatment. The series has no comparator with which to measure the reduction. It shows that subsequent microthrombectomy remains part of follow-up care even when foam expression and phlebectomy have been performed initially.
References
- Rabe E, Breu FX, Flessenkämper I, et al. Sclerotherapy in the treatment of varicose veins: S2k guideline of the Deutsche Gesellschaft für Phlebologie (DGP) in cooperation with the following societies: DDG, DGA, DGG, BVP. Hautarzt. 2021;72(suppl 2):23–36. https://doi.org/10.1007/s00105-020-04705-0
- Scultetus AH, Villavicencio JL, Kao TC, et al. Microthrombectomy reduces postsclerotherapy pigmentation: multicenter randomized trial. J Vasc Surg. 2003;38(5):896–903. https://doi.org/10.1016/S0741-5214(03)00920-0
- Verlato F, Zucchetta P, Prandoni P, et al. An unexpectedly high rate of pulmonary embolism in patients with superficial thrombophlebitis of the thigh. J Vasc Surg. 1999;30(6):1113–1115. https://doi.org/10.1016/s0741-5214(99)70051-0
- Gloviczki P, Lawrence PF, Wasan SM, et al. The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II. J Vasc Surg Venous Lymphat Disord. 2024;12(1):101670. https://doi.org/10.1016/j.jvsv.2023.08.011